|
Apr 16
|
CareDx Appoints John W. Hanna as its New President and Chief Executive Officer
|
|
Apr 9
|
CareDx and Collaborators Present Latest Cardiothoracic Advancements at the 2024 International Society for Heart and Lung Transplantation Meeting
|
|
Apr 1
|
How CareDx (CDNA) Stock Stands Out in a Strong Industry
|
|
Mar 11
|
CareDx Appoints Bryan Riggsbee to Its Board of Directors
|
|
Jan 11
|
CareDx Adds to AlloSure Kidney and HeartCare Utility and Clinical Data at 2024 American Society of Transplant Surgeons Winter Symposium
|
|
Jan 9
|
CareDx Reports Preliminary Revenue Results for Fourth Quarter and Full Year 2023
|
|
Dec 19
|
CareDx Joins Forces with the National Foundation for Transplants to Improve Post-Transplant Medication Adherence
|
|
Dec 8
|
How Much Upside is Left in CareDx (CDNA)? Wall Street Analysts Think 26.72%
|
|
Aug 11
|
CareDx Comments on Issuance of Proposed LCD for Molecular Testing for Solid Allograft Rejection
|
|
Aug 9
|
Compared to Estimates, CareDx (CDNA) Q2 Earnings: A Look at Key Metrics
|
|
Aug 8
|
CareDx (CDNA) Reports Q2 Loss, Tops Revenue Estimates
|
|
Aug 8
|
CareDx Reports Second Quarter 2023 Results
|
|
Aug 7
|
CareDx Announces District Court Judge Bars Natera from Falsely Advertising and Overstating the Scientific Performance of its Prospera Transplant Test
|